Deconstructing Voice Therapy: Towards Enhanced Communication Outcomes
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16-65
SponsorEmory University
About this trial
This research study aims to evaluate the effect of treatment delivery method on voice outcomes over 12 months in people with a primary complaint of a voice problem, diagnosed with either non-phonotraumatic vocal hyperfunction, also known as primary muscle tension dysphonia (MTD) or phonotraumatic vocal hyperfunction, also known as benign vocal fold lesions (lesions).
The secondary objectives are:
* To evaluate acoustic correlates of clear speech and the relationship to vocal acoustic and patient-reported voice outcomes. * To determine the association between overall dysphonia outcomes and adoption of clear speech.
Eligibility criteria
Qualifiers
Non-smoking
Diagnosis of either primary muscle tension dysphonia of the hyperadducted type or benign vocal fold lesions.
No neuro-laryngologic or age-related vocal fold changes (e.g., atrophy)
No history of voice therapy or voice surgery in the last year
Disqualifiers
History of voice therapy or voice surgery in the last year
Serious chronic medical condition that may affect voice (per patient report)
Abnormal hearing ability (despite appropriate amplification)
Other laryngeal disorders not attributed to primary MTD and benign vocal fold lesions,
Trial design
Treatments tested in this trial
- Hierarchical method
- Non Hierarchical method
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Emory University
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator
Source ClinicalTrials.gov